Aficamten + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Conditions
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Trial Timeline
Aug 30, 2023 → Sep 1, 2026
NCT ID
NCT06081894About Aficamten + Placebo
Aficamten + Placebo is a phase 3 stage product being developed by Sanofi for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06081894. Target conditions include Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06081894 | Phase 3 | Active |
Competing Products
20 competing products in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |